针对HER2-阳性炎症性乳腺癌的新辅助HER2-向治疗方案,含或不含 antracyclines:一个多中心的回顾性研究
Toshiaki Iwase1,2,3, Nithya Sridhar1, Megumi Kai1,2
1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Breast cancer research and treatment
|August 2, 2025
概括
对HER2阳性炎症性乳腺癌 (IBC) 的新辅助疗法添加人环素并没有改善病理完整反应率. 然而,含有环素的疗法可能为这些患者提供更长时间的疾病控制.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 临床试验 临床试验
背景情况:
- 对HER2阳性乳腺癌的新辅助治疗通常涉及化疗,特拉斯图祖马布和珀图祖马布.
- 人环素是一种化学疗法药物,有时包括在新辅助剂方案中.
- 人环素在HER2阳性炎症性乳腺癌 (IBC) 中的作用尚不清楚.
研究的目的:
- 为了比较HER2-阳性原发性IBC患者的新辅助疗程的病理完整响应 (pCR) 率,使用或不使用Anthracyclines.
- 评估二次结果,包括局部或区域复发时间 (TLRR),无事件生存率 (EFS) 和整体生存率 (OS).
主要方法:
- 在2014-2021年期间接受治疗的101名HER2-阳性原发性IBC患者的回顾性审查.
- 患者接受了TCHP (docetaxel,卡博普拉丁,特拉斯图祖马布,珀图祖马布) 或THP-AC (docetaxel,特拉斯图祖马布,珀图祖马布,多克索鲁比辛,环胺) 的新辅助疗法.
- 统计分析包括单变量和多变量后勤和考克斯回归模型.
主要成果:
- 在TCHP (48.7%) 和THP-AC (53.2%) 方案之间没有观察到pCR率的显著差异 (p=0.659).
- 多变量分析显示,在调整年龄和雌激素受体状态后,pCR和治疗方案类型之间没有关联.
- 与TCHP相比,THP-AC疗法与较长的TLRR (HR 0.279) 和EFS (HR 0.462) 相关,但在OS上没有差异.
结论:
- 含有人类环素的新辅助剂方案不会改善HER2-阳性IBC中的pCR.
- 然而,这些疗法可能会在HER2阳性IBC患者中延长疾病控制 (TLRR和EFS).
- 需要进一步的研究来确定对HER2-阳性IBC的最佳新辅助疗法.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
01:29Inflammatory Bowel Disease IV: Pharmacological Management
190
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
190
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
260
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
260
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
233
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
233